AI news impact · US stocks

Inovio Pharmaceuticals, Inc. (INO) news impact

On 2026-11-11 Wave Radar's AI rated the news on Inovio Pharmaceuticals, Inc. as neutral (impact score +55%).

Inovio reported Q3 results and is preparing the commercial launch of its first approved product, VOCERYQ, following FDA accelerated approval for RRP.

Direction
Neutral
Impact score
+55%
Confidence
85%
Headlines read
4
Date
2026-11-11
Open INO news in Wave Radar

AI assessment

The transition to commercial stage with VOCERYQ marks a key milestone, offering new revenue potential while quarterly burn remains in focus.

Sector impact

Introduces competitive pressure for peers targeting RRP like Precigen, providing a mild catalyst for the rare disease biotech space.

Headlines the AI read

More on Inovio Pharmaceuticals, Inc.

INO valuation · INO gamma exposure

How the rating works

After each close Wave Radar collects the day's headlines and filings for a stock and asks an AI model what they mean for it. The rating is one of five levels from major negative to major positive; the impact score runs from −100% to +100%, and a rating built on a single uncorroborated source is capped. It describes the news, not the price outlook.

Figures are generated automatically from Wave Radar's published market data and refresh after each market close.